BeiGene Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- BeiGene's estimated annual revenue is currently $180.4M per year.
- BeiGene received $800.0M in venture funding in January 2018.
- BeiGene's estimated revenue per employee is $155,000
- BeiGene's total funding is $529.6M.
- BeiGene has 1164 Employees.
- BeiGene grew their employee count by 44% last year.
- BeiGene currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
|Cell Signaling ...||$89.4M||577||N/A||N/A||-||N/A|
What Is BeiGene?
BeiGene, Ltd. (NASDAQ: BGNE) is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,300 employees in China, the United States (Cambridge, MA; Fort Lee, NJ; Emeryville, CA & San Mateo, CA), Switzerland and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for the treatment of cancer. BeiGene is working to create combination solutions aimed at having both a meaningful and lasting impact on cancer patients. For more information, see www.beigene.com.keywords:Biotechnology,Healthcare
Number of Employees
Employee Growth %
J Capital alleged that BeiGene has been stuck with an unsellable product, Celgene, of which actual sales were 57 percent lower than it ...
Beigene Ltd (NASDAQ:BGNE)'s share price traded down 6.8% during mid-day trading on Thursday after an insider sold shares in the company ...
On Thursday, shares of BeiGene, Ltd. (NASDAQ:BGNE) marked $131.03 per share versus a previous $140.56 closing price. With having a ...
BeiGene Executive Hires
|2016-05-05||Ji Li||EVP & Global Head Business Development||Article|
|2016-08-25||Amy Peterson||Chief Medical Officer, Immuno-oncology||Article|
|2016-09-07||Jane Huang||Chief Medical Officer, Hematology||Article|
|2016-10-04||Ross Pettit||SVP Global Development Operations||Article|
|2018-05-02||Xiaobin Wu||General Manager of China/President||Article|